The Global Breast Cancer Therapeutics Market, which stood at US$ 17,868.8 Mn in 2018, will reach [US$ 38,573.5 Mn] by the end of 2026. If these figures prove true, the global breast cancer therapeutics market will rise at a CAGR of 10.2% between 2018 and 2026.
Request a Sample Research Report : https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/breast-cancer-therapeutics-market-100163
Some of the Main Key Players Covered in the Report
- Genentech (F. Hoffmann-La Roche Ltd)
- Eli Lilly and Company
- Celgene Corporation
- Pfizer Inc.
- Eisai Co. Ltd.
- Kyowa Kirin
- Bristol Myers Squibb
- Mayne Pharma Group Limited
- Valeant Pharmaceuticals
Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/breast-cancer-therapeutics-market-100163
North America to Remain Dominant on Account of Presence of Skilled Professionals
The increasing number of breast cancer cases all over the world is anticipated to boost the global market at promising rates, finds Fortune Business Insights in a new study. The study is titled, “Breast Cancer Therapeutics Market: Global Market Analysis, Insights, and Forecasts”.
The market in North America is currently leading the global landscape, supported by the presence of well-established healthcare infrastructure and rising uptake of advanced facilities in the region. In 2018, North America generated a revenue of US$ 8,033.8 Mn because of the increasing prevalence of breast cancer in the region.
In addition to this, the region boasts the presence of several leading market players and skilled professionals. Besides this, governments of developed nations such as Canada and the U.S. are providing health insurance for cancer diagnostics. Spurred by these factors the breast cancer therapeutics market is likely to flourish in North America to emerge dominant.
- Targeted Therapy
- Ado-Trastuzumab Emtansine
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Cancer Type
- Hormone Receptor
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Looming Patent Expiries Fuels Demand for Generic Drugs
According to the World Health Organization, in 2018, an approximate of 627,000 women, which is tantamount to 15% of all cancer deaths worldwide, succumbed to breast cancer. The rising incidence of breast cancer is one of the chief drivers of the global breast cancer therapeutics market.
The global market is likely to witness the prevalence of high competition. According to the report, Genentech, Inc. (F. Hoffmann-La Roche Ltd) held the dominant share in the market in 2018. Its diverse product portfolio backs growth of the company in a targeted and chemotherapy segment.
More Trending Topics from Fortune Business Insights:
Hemostatic Agents Market 2020: Industry Advancement, Comprehensive Insights, Growth Factors, Regional Analysis Forecast by 2025
Wearable Medical Devices Market Demand, Global Trend, Industry Analysis, Business Growth, Top Key Players by Forecast to 2026
Plasma Fractionation Market Global Growth by Top Key Players are Grifols, Baxter, CSL, LFB, Shire, Japan Blood Products Organization and more Forecast to 2026
Cardiovascular Drugs Market 2020: Research Report, Trends, Analysis, Advancements, Share and Size Forecast till 2026